Table 3 A sampling of the combinations of IGF-1R targeted drugs and other targeted agents that have entered clinical trials
From: IGF-1R targeting in cancer – does sub-cellular localization matter?
IGF-1R inhibitor | Co-targeted protein | Partner drug | Tumors | NCT Number |
|---|---|---|---|---|
Ganitumab | mTOR | Evorolimus | Advanced cancer | NCT01061788 |
R1507 | mTOR | Evorolimus | Advanced solid tumors | NCT00985374 |
Cixutumumab | mTOR | Everolimus | Neuroendocrine carcinoma | NCT01204476 |
Cixutumumab | mTOR | Everolimus | Solid tumors, NSCLC | NCT01061788 |
Cixutumumab | mTOR | Temsirolumus | Pediatric solid tumors | NCT00880282 |
Cixutumumab | mTOR | Temsirolumus | Sarcoma | NCT01614795 |
Cixutumumab | mTOR | Temsirolumus | Sarcoma | NCT01016015 |
Cixutumumab | mTOR | Temsirolumus | Metastatic prostate cancer | NCT01026623 |
Cixutumumab | mTOR | Temsirolumus | Breast cancer | NCT00699491 |
AVE1642 | proteasome | Bortezomib | Multiple myeloma | NCT01233895 |
OSI-906 | EGFR | Erlotinib | Breast cancer | NCT01205685 |
OSI-906 | EGFR | Erlotinib | Metastatic breast cancer | NCT01013506 |
AVE1642 | EGFR | Erlotinib | Liver carcinoma | NCT00791544 |
Cixutumumab | EGFR | Erlotinib | NSCLC | NCT00778167 |
Cixutumumab | EGFR | Erlotinib | Pancreatic cancer | NCT00617708 |
Ganitumab | HER-2 | Trastuzumab | Breast cancer | NCT01479179 |
Cixutumumab | EGFR/ | Lapatinib | Breast cancer | NCT00684983 |
Cixutumumab | MEK-1/2 | Selumetinib | Adult solid neoplasms | NCT01061749 |
Ganitumab | SFK | Dasatinib | Rhabdomyosarcoma | NCT03041701 |
Figitumumab | GH | Pegvisomant | Advanced solid tumors | NCT00976508 |
Ganitumab | CDK4/6 | Pablociclib | Relapsed Ewsing sarcoma | NCT04129151 |
BIIB022 | Kinases | Sorafenib | Hepatocellular carcinoma | NCT00956436 |
AVE164 | Kinases | Sorafenib + Erlotinib) | Metastatic liver cancer | NCT00791544 |